Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 9,035 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pulmonary Clear all
Completed Phase 2 Interventional

Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

NCT00020878
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
45 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 28, 2026, 11:08 PM EDT
Active, not recruiting No phase listed Observational

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

NCT04430725
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Sarcoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Computed Tomography with Contrast, Microwave Ablation, Questionnaire Administration, Wedge Excision
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Not yet recruiting Not applicable Interventional

A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter

NCT07788989
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
VARIPULSE Catheter System (PVI), VARIPULSE Catheter System (PVI and PWI)
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Terminated Phase 1Phase 2 Interventional

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

NCT00093132
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung, Lung Cancer
Interventions
Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

NCT02716116
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
TAK-788
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

NCT00417248
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Radiotherapy, Sorafenib
Drug · Procedure
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Galesburg, Illinois • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 28, 2026, 11:08 PM EDT
Withdrawn No phase listed Observational

Bronchiectasis: Evaluation of an Educational Intervention

NCT01315626
View directory record Official record
Conditions
Bronchiectasis
Interventions
Primary Care Educational event
Other
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Shelbyville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

NCT00398216
View directory record Official record
Conditions
Thrombosis, Hip Replacement
Interventions
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Hartford, Connecticut • Sarasota, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Graphic Cigarette Warnings

NCT02247908
View directory record Official record
Conditions
Smoking
Interventions
Surgeon General's Warning, Graphic Warning
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Oakland, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Not applicable Interventional Results available

EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer

NCT04159025
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC
Interventions
CoreDx Pulmonary Mini-Forceps
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 28, 2026, 11:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

NCT07730021
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
ASP388B, Pembrolizumab, Carboplatin, Oxaliplatin, 5-fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Lake Success, New York • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106
View directory record Official record
Conditions
Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions
AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Not applicable Interventional Results available

Flexibility and Strength Training in Asthma

NCT02370004
View directory record Official record
Conditions
Asthma
Interventions
Resistive Flexibility and Strength Training
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 28, 2026, 11:08 PM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00006347
View directory record Official record
Conditions
Lung Cancer
Interventions
indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Belleville, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2009 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 1 Interventional

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

NCT03326752
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
DV281, Breath Actuated Nebulizer, DV281 (RP2D), Approved Anti-PD-1 Inhibitor
Drug · Device
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 28, 2026, 11:08 PM EDT
Terminated Phase 1 Interventional Results available

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

NCT05374538
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
VIC-1911, sotorasib
Drug
Lead sponsor
Vitrac Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Results available

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00481078
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
vorinostat, paclitaxel, carboplatin, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 28, 2026, 11:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07038343
View directory record Official record
Conditions
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions
AVZO-1418, Combination Agent 1, Combination Agent 2
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Completed No phase listed Observational

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

NCT01294280
View directory record Official record
Conditions
Lung Cancer
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 28, 2026, 11:08 PM EDT
Completed Phase 2 Interventional

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

NCT00059722
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
ZD6474, Placebo, ZD1839
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
18
States / cities
Pine Bluff, Arkansas • Los Angeles, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 28, 2026, 11:08 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Double Lumen Tube Placement Techniques

NCT02495259
View directory record Official record
Conditions
Airway Morbidity, Intubation Complication, Tracheal Intubation Morbidity, Anesthesia Intubation Complication, Failed or Difficult Intubation, Sequela
Interventions
ZU-bend stylet, GlideScope, GlideRite stylet, Macintosh blade, Regular Double-lumen endobronchial tube (DLT) Stylet
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 28, 2026, 11:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Osimertinib, Lazertinib, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
20
States / cities
Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 11:08 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

NCT05215327
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 28, 2026, 11:08 PM EDT